A Genetically Determined Dose-Volume Histogram Predicts for Rectal Bleeding among Patients Treated With Prostate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 5, 2007, Pages 1410-1416

  Cesaretti, Jamie A ^a   Stock, Richard G ^a   Atencio, David P ^a   Peters, Sheila A ^a   Peters, Christopher A ^a   Burri, Ryan J ^a   Stone, Nelson N ^a   Rosenstein, Barry S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse radiotherapy effects; Brachytherapy; DVH; Genetic predictors; Prostate cancer

Indexed keywords

DNA SEQUENCES; GENETIC ENGINEERING; HEALTH CARE; MEDICAL PROBLEMS; RADIOTHERAPY;

ADVERSE RADIOTHERAPY EFFECTS; BRACHYTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GENETIC PREDICTORS; PROSTATE CANCER;

RADIATION EFFECTS;

IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; EXTERNAL BEAM RADIOTHERAPY; FISHER EXACT TEST; FOLLOW UP; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; QUANTITATIVE STUDY; RADIATION DOSE; RECTUM HEMORRHAGE;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, RADIATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; IMPOTENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PALLADIUM; PROCTITIS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RADIOISOTOPES; RECTAL DISEASES; RECTUM; TUMOR SUPPRESSOR PROTEINS;

EID: 34547421746     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.02.052     Document Type: Article

References (49)

1. Stock R.G., Cesaretti J.A., and Stone N.N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 810-816
2. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 4 pt 1 (2006) 1415-1419
3. Zhou P., Chen M.H., McLeod D., et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
4. Stone H.B., Coleman C.N., Anscher M.S., et al. Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol 4 (2003) 529-536
5. Bentzen S.M., and Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol 4 (1994) 68-80
6. Jackson A., Kutcher G.J., and Yorke E.D. Probability of radiation induced complications for normal tissues with parallel architecture subject to non-uniform irradiation. Med Phys 20 (1993) 613-625
7. Diaz A., Roach M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
8. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 2460-2468
9. Pilepich M.V., Asbell S.O., Krall J.M., et al. Correlation of radiotherapeutic parameters and treatment-related morbidity. Analysis of RTOG study 7706. Int J Radiat Oncol Biol Phys 13 (1987) 1007-1012
10. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 35 (1996) 251-257
11. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
12. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 10 (2006) 82-86
13. Sanguineti G., Cavey M.L., Endres E.J., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. Strahlenther Onkol 182 (2006) 543-549
14. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
15. Xia P., Pickett B., Vigneault E., et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 51 (2001) 244-254
16. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1753
17. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3 (2003) 155-168
18. Telatar M., Wang Z., Udar N., et al. Ataxia-telangiectasia: Mutations in ATM cDNA detected by protein-truncation screening. Am J Hum Genet 59 (1996) 40-44
19. Morgan J.L., Holcomb T.M., and Morrissey R.W. Radiation reaction in ataxia-telangiectasia. Am J Dis Child 116 (1968) 557-558
20. Gatti R.A., Tward A., and Concannon P. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 68 (1999) 419-423
21. Cesaretti J.A., Stock R.G., Lehrer S., et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 196-202
22. 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
23. 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 342-353
24. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63 (2005) 150-154
25. American Joint Committee on Cancer. Cancer staging manual (1992), Lippincott, Philadelphia
26. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound guided three dimensional transperineal prostate implantation. Int J Radiat Oncol Bio Phys 32 (1995) 219-225
27. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
28. Williamson J.F., Coursey B.M., DeWerd L.A., et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: Implications for dose specification and prescription. Med Phys 27 (2000) 634-642
29. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and post-treatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
30. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
31. Stock R.G., Stone N.N., and Iannuzzi C.M. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 35 (1996) 267-273
32. Stock R.G., Kao J., and Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165 (2001) 436-439
33. Atencio D.P., Iannuzzi C.M., Green S., et al. Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environ Mol Mutagen 38 (2001) 200-208
34. Bernstein J.L., Teraoka S., Haile R.W., et al., WECARE Study Collaborative Group. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 21 (2003) 542-550
35. Sommer S.S., Buzin C.H., Jung M., et al. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet 134 (2002) 25-34
36. Sommer S.S., Jiang Z., Feng J., et al. ATM missense mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet 145 (2003) 115-120
37. Thornstenson Y.R., Shen P., Tusher V.G., et al. Global analysis of ATM polymorphism reveals significant functional constraint. Am J Hum Genet 69 (2001) 396-412
38. O'Brien P.C. Radiation injury of the rectum. Radiother Oncol 60 (2001) 1-14
39. Hopewell J.W., Calvo W., Jaenke R., et al. Microvasculature and radiation damage. Recent Results Cancer Res 130 (1993) 1-16
40. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
41. Stone N.N., and Stock R.G. Complications following permanent prostate brachytherapy. Eur Urol 41 (2002) 427-433
42. Walsh P.C., and Mostwin J.L. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 56 (1984) 694-697
43. Zelefsky M.J., and Eid J.F. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 40 (1998) 129-133
44. Pawlik T.M., and Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 928-942
45. Khanna K.K., Lavin M.F., Jackson S.P., et al. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 8 (2001) 1052-1065
46. Meyer A., John E., Dork T., et al. Breast cancer in female carriers of ATM gene alterations: Outcome of adjuvant radiotherapy. Radiother Oncol 72 (2004) 319-323
47. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
48. Fisher B. From Halsted to prevention and beyond: Advances in the management of breast cancer during the twentieth century. Eur J Cancer 35 (1999) 1963-1973
49. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials. Lancet 366 (2005) 2087-2106